- Home
- NYXH vs ADAP Comparison
NYXH vs ADAP Comparison
Compare NYXH & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYXH
- ADAP
- Stock Information
- Founded
- NYXH 2009
- ADAP 2008
- Country
- NYXH Belgium
- ADAP United Kingdom
- Employees
- NYXH N/A
- ADAP N/A
- Industry
- NYXH Medical/Dental Instruments
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- NYXH Health Care
- ADAP Health Care
- Exchange
- NYXH Nasdaq
- ADAP Nasdaq
- Market Cap
- NYXH 261.1M
- ADAP 212.3M
- IPO Year
- NYXH 2021
- ADAP 2015
- Fundamental
- Price
- NYXH $8.22
- ADAP $0.59
- Analyst Decision
- NYXH Strong Buy
- ADAP Strong Buy
- Analyst Count
- NYXH 5
- ADAP 4
- Target Price
- NYXH $17.00
- ADAP $3.16
- AVG Volume (30 Days)
- NYXH 26.6K
- ADAP 2.0M
- Earning Date
- NYXH 11-06-2024
- ADAP 11-13-2024
- Dividend Yield
- NYXH N/A
- ADAP N/A
- EPS Growth
- NYXH N/A
- ADAP N/A
- EPS
- NYXH N/A
- ADAP N/A
- Revenue
- NYXH $5,668,079.00
- ADAP $175,041,000.00
- Revenue This Year
- NYXH $37.10
- ADAP $180.15
- Revenue Next Year
- NYXH $418.12
- ADAP N/A
- P/E Ratio
- NYXH N/A
- ADAP N/A
- Revenue Growth
- NYXH 32.65
- ADAP 146.27
- 52 Week Low
- NYXH $4.00
- ADAP $0.42
- 52 Week High
- NYXH $20.00
- ADAP $2.05
- Technical
- Relative Strength Index (RSI)
- NYXH 30.23
- ADAP 26.22
- Support Level
- NYXH $8.10
- ADAP $0.75
- Resistance Level
- NYXH $10.01
- ADAP $0.83
- Average True Range (ATR)
- NYXH 0.47
- ADAP 0.07
- MACD
- NYXH -0.19
- ADAP -0.01
- Stochastic Oscillator
- NYXH 6.28
- ADAP 2.36
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.